Kuusk, T;
Szabados, B;
Liu, WK;
Powles, T;
Bex, A;
(2019)
Cytoreductive nephrectomy in the current treatment algorithm.
Therapeutic Advances in Medical Oncology
, 11
pp. 1-7.
10.1177/1758835919879026.
Preview |
Text
Bex 1758835919879026.pdf - Published Version Download (200kB) | Preview |
Abstract
The two recent prospective randomized trials CARMENA and SURTIME have changed the therapy paradigm of metastatic renal cell carcinoma. The CARMENA trial was conducted to investigate whether cytoreductive nephrectomy (CN) is required in the targeted therapy area, whereas SURTIME studied whether deferred CN in combination with sunitinib can be used to identify patients with inherent targeted therapy resistance. In the current review, we provide a comprehensive discussion of two randomized studies and the current evidence with up-do-date algorithms for treating primary metastatic clear-cell renal cell carcinoma in the era of targeted therapy and immune-checkpoint inhibition.
| Type: | Article |
|---|---|
| Title: | Cytoreductive nephrectomy in the current treatment algorithm |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/1758835919879026 |
| Publisher version: | https://doi.org/10.1177/1758835919879026 |
| Language: | English |
| Additional information: | This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology, cytoreductive nephrectomy, immunotherapy, metastatic renal cell carcinoma, renal cell carcinoma, sunitinib, systemic therapy, targeted therapy, tyrosine kinase inhibitors, RENAL-CELL CARCINOMA, TARGETED THERAPY, INTERFERON-ALPHA, SURVIVAL, SUNITINIB, CANCER, MODEL |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci > Department of Surgical Biotechnology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10085827 |
Archive Staff Only
 |
View Item |
